{"doi":"10.17615/tmgg-w910","title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","abstract":"Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with relapsed or refractory multiple myeloma who had ≥2 prior lines of therapy, one of which had to be bortezomib-based. Fourteen initial patients received siltuximab alone, 10 of whom had dexamethasone added for suboptimal response; 39 subsequent patients were treated with concurrent siltuximab and dexamethasone. Patients received a median of 4 prior lines of therapy, 83% were relapsed and refractory, and 70% refractory to their last dexamethasone-containing regimen. Suppression of serum C-reactive protein levels, a surrogate marker of IL6 inhibition, was demonstrated. There were no responses to siltuximab but combination therapy yielded a partial (17%) + minimal (6%) response rate of 23%, with responses seen in dexamethasone-refractory disease. The median time to progression, progression-free survival and overall survival for combination therapy was 4.4, 3.7 and 20.4 months, respectively. Haematological toxicity was common but manageable. Infections occurred in 57% of combination-treated patients, including ≥grade 3 infections in 18%. Further study of siltuximab in modern corticosteroid-containing myeloma regimens is warranted, with special attention to infection-related toxicity.","journal":"UNC Libraries","year":2020,"id":140022,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9595,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":407168,"name":"Suzanne Lentzsch","orcid":"0000-0003-1708-7344","position":1,"is_corresponding":false},{"id":603588,"name":"Pieter Sonneveld","orcid":"0000-0002-0808-2237","position":2,"is_corresponding":false},{"id":402368,"name":"Sonja Zweegman","orcid":"0000-0002-5011-1820","position":3,"is_corresponding":false},{"id":603589,"name":"Hong Xie","orcid":"0000-0001-9715-955X","position":4,"is_corresponding":false},{"id":599730,"name":"Xiang Qin","orcid":"0000-0003-1524-027X","position":5,"is_corresponding":false},{"id":268268,"name":"Peter M. Voorhees","orcid":"0000-0003-1661-718X","position":6,"is_corresponding":false},{"id":604243,"name":"Britte Kranenburg","orcid":null,"position":7,"is_corresponding":false},{"id":375057,"name":"George Somlo","orcid":null,"position":8,"is_corresponding":false},{"id":25426,"name":"Amrita Krishnan","orcid":null,"position":9,"is_corresponding":false},{"id":239467,"name":"Robert Z. Orlowski","orcid":"0000-0002-5723-4129","position":10,"is_corresponding":false},{"id":599732,"name":"Helgi van de Velde","orcid":"0009-0004-4126-8289","position":11,"is_corresponding":false},{"id":603590,"name":"Richard C. Frank","orcid":"0000-0002-5923-7171","position":12,"is_corresponding":false},{"id":404734,"name":"Sheeba K. Thomas","orcid":"0000-0001-8596-7058","position":13,"is_corresponding":false},{"id":604244,"name":"Brett M. Hall","orcid":null,"position":14,"is_corresponding":false},{"id":207304,"name":"Tineke Casneuf","orcid":null,"position":15,"is_corresponding":false},{"id":25424,"name":"Sundar Jagannath","orcid":"0000-0003-2934-6518","position":16,"is_corresponding":false},{"id":604245,"name":"Pierre W. Wijermans","orcid":null,"position":17,"is_corresponding":false},{"id":604242,"name":"Robert Manges","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:17:13.583586Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}